ЛИТЕРАТУРА
1. Nakashima R., Yamane K., Kamei N. et aL. Low serum LeveLs of totaL and high-moLecuLar-weight adiponectin predict the deveLopment of metaboLic syndrome in Japanese-Americans // J. EndocrinoL. Invest. 2011. VoL. 34, N 8. P. 615-619.
2. Аметов А.С., Камынина Л.Л., Ахмедова З.Г. Клинические аспекты генетики, нутриогенетики и фармакогенетики сахарного диабета 2-го типа // Тер. арх. 2015. Т. 87, № 8. С. 124-131.
3. de Luis D.A., IzaoLa O., de La Fuente B. et aL. rs1501299 PoLymorphism in the adiponectin gene and their association with totaL adiponectin LeveLs, insuLin resistance and metaboLic syndrome in obese subjects // Ann. Nutr. Metab. 2016. VoL. 69, N 3-4. P. 226-231.
4. Riestra P., Gebreab S.Y., Xu R. et aL. Gender-specific associations between ADIPOQ gene poLymorphisms and adiponectin LeveLs and obesity in the Jackson Heart Study cohort // BMC Med. Genet. 2015. VoL. 16. P. 65.
5. HoLLand W.L., Xia J.Y., Johnson J.A. et aL. InducibLe overexpression of adiponectin receptors highLight the roLes of adiponectin-induced ceramidase signaLing in Lipid and gLucose homeostasis // MoL. Metab. 2017. VoL. 6, N 3. P. 267-275.
6. EL Husseny M.W., Mamdouh M., Shaban S. et aL. Adipokines: potentiaL therapeutic targets for vascuLar dysfunction in type II diabetes meLLitus and obesity // J. Diabetes Res. 2017. VoL. 2017. ArticLe ID 8095926.
7. Пашенцева А., Вербовой А., Шаронова Л. Адипонектин: биологические и патофизиологические эффекты // Врач. 2016. № 8. С. 12-15.
8. Терещенко И.В., Каменских Я.А., Суслина А.А. Адипонектин в норме и патологии // Тер. арх. 2016. Т. 88, № 12. С. 126-132.
9. Ruan H., Dong L.Q. Adiponectin signaLing and function in insuLin target tissues // J. MoL. CeLL. BioL. 2016. VoL. 8, N 2. P. 101-109.
10. Liu Z., Xiao T., Peng X. et aL. APPLs: More than just adiponectin receptor binding proteins // CeLL SignaL. 2017. VoL. 32. P. 76-84.
11. Reibe-PaL S., Febbraio M.A. Adiponectin serenades ceramidase to improve metaboLism // MoL. Metab. 2017. VoL. 6, N 3. P. 233-235.
12. Weber K.S., Strassburger K., Pacini G. et aL. CircuLating adi-ponectin concentration is inverseLy associated with gLucose toLerance and insuLin secretion in peopLe with newLy diagnosed diabetes // Diabet. Med. 2017. VoL. 34, N 2. P. 239-244.
13. Ntzouvani A., FragopouLou E., Panagiotakos D. et aL. Reduced circuLating adiponectin LeveLs are associated with the metaboLic syndrome independentLy of obesity, Lipid indices and serum insuLin LeveLs: a cross-sectionaL study // Lipids HeaLth Dis. 2016. VoL. 15, N 1. P. 140.
14. Banerjee A., Khemka V.K., Roy D. et aL. RoLe of serum adiponectin and vitamin D in prediabetes and diabetes meLLitus // Can. J. Diabetes. 2017. VoL. 41, N 3. P. 259-265.
15. Zhang J., Xia L., Zhang F. et aL. A noveL mechanism of diabetic vascuLar endotheLiaL dysfunction: hypoadiponectinemia-induced NLRP3 infLammasome activation // Biochim. Biophys. Acta. 2017. VoL. 1863, N 6. P. 1556-1567.
16. Zhao W., Wu C., Li S., Chen X. Adiponectin protects paLmitic acid induced endotheLiaL infLammation and insuLin resistance via reguLating ROS/IKKβ pathways // Cytokine. 2016. VoL. 88. P. 167-176.
17. Okamoto Y. Adiponectin provides cardiovascuLar protection in metaboLic syndrome // CardioL. Res. Pract. 2011. VoL. 2011. ArticLe ID 313179.
18. Gorgui J., Gasbarrino K., Georgakis M.K. et aL. CircuLating adiponectin LeveLs in reLation to carotid atheroscLerotic pLaque presence, ischemic stroke risk, and mortaLity: a systematic review and meta-anaLyses // MetaboLism. 2017. VoL. 69. P. 51-66.
19. Kizer J.R. Adiponectin, cardiovascuLar disease, and mortaLity: parsing the duaL prognostic impLications of a compLex adipokine // MetaboLism. 2014. VoL. 63, N 9. P. 1079-1083.
20. BeLaLcazar L.M., Lang W., Haffner S.M. et aL. Improving adiponectin LeveLs in individuaLs with diabetes and obesity: insights from Look AHEAD // Diabetes Care. 2015. VoL. 38, N 8. P. 1544-1550.
21. Gasbarrino K., Gorgui J., Nauche B. et aL. CircuLating adiponectin and carotid intima-media thickness: a systematic review and meta-anaLysis // MetaboLism. 2016. VoL. 65, N 7. P. 968-986.
22. Gasbarrino K., Zheng H., Hafiane A. et aL. Decreased adiponectin-mediated signaLing through the AdipoR2 pathway is associated with carotid pLaque instabiLity // Stroke. 2017. VoL. 48, N 4. P. 915-924.
23. Sente T., Van Berendoncks A.M., Hoymans V.Y., Vrints C.J. Adiponectin resistance in skeLetaL muscLe: pathophysioLogicaL impLications in chronic heart faiLure // J. Cachexia Sarcopenia MuscLe. 2016. VoL. 7, N 3. P. 261-274.
24. Sente T., Gevaert A., Van Berendoncks A. et aL. The evoLving roLe of adiponectin as an additive biomarker in HFrEF // Heart FaiL. Rev. 2016. VoL. 21, N 6. P. 753-769.
25. Peri-Okonny P.A., Ayers C., MaaLouf N. et aL. Adiponectin predicts against incident hypertension independent of body fat distribution: observations from the DaLLas Heart Study // Diabetes Metab. Res. Rev. 2017. VoL. 33, N 2.
26. Kim D.H., Kim C., Ding E.L. et aL. Adiponectin LeveLs and the risk of hypertension: a systematic review and meta-anaLysis // Hypertension. 2013. VoL. 62, N 1. P. 27-32.
27. Lopez-JaramiLLo P., Gomez-ArbeLaez D., Lopez-Lopez J. et aL. The roLe of Leptin/adiponectin ratio in metaboLic syndrome and diabetes // Horm. MoL. BioL. CLin. Investig. 2014. VoL. 18, N 1. P. 37-45.
28. Kim J.Y., Yadav D., Ahn S.V., Koh S.B. A prospective study of serum adiponectin and regression of metaboLic syndrome: the ARIRANG study // Biochem. Biophys. Res. Commun. 2015. VoL. 466, N 2. P. 201-205.
29. Kang D.R., Yadav D., Koh S.B. et aL. Impact of serum Leptin to adiponectin ratio on regression of metaboLic syndrome in high-risk individuaLs: The ARIRANG Study // Yonsei Med. J. 2017. VoL. 58, N 2. P. 339-346.
30. Iwan-Zietek I., Ruszkowska-Ciastek B., MichaLska M. et aL. Association of adiponectin and Leptin-to-adiponectin ratio with the function of pLateLets in morbidLy obese patients // J. PhysioL. PharmacoL. 2016. VoL. 67, N 4. P. 555-561.
31. Bairwa S.C., Rajapurohitam V., Gan X.T. et aL. Cardiomyocyte antihypertrophic effect of adipose tissue conditioned medium from rats and its abrogation by obesity is mediated by the Leptin to adiponectin ratio // PLoS One. 2016. VoL. 11, N 1. ArticLe ID e0145992.
32. DuLLaart R.P., Gruppen E.G., ConneLLy M.A. et aL. GLycA, a biomarker of infLammatory gLycoproteins, is more cLoseLy reLated to the Leptin/adiponectin ratio than to gLucose toLerance status // CLin. Biochem. 2015. VoL. 48, N 12. P. 811-814.
33. Gumanova N.G., GavriLova N.E., Chernushevich O.I. et aL. Ratios of Leptin to insuLin and adiponectin to endotheLin are sex-dependentLy associated with extent of coronary atheroscLerosis // Biomarkers. 2017. VoL. 22, N 3-4. P. 239-245.
34. Upadhyaya S., Kadamkode V., Mahammed R. et aL. Adiponectin and IL-6: mediators of infLammation in progression of heaLthy to type 2 diabetes in Indian popuLation // Adipocyte. 2014. VoL. 3, N 1. P. 39-45.
35. Xu X., Lai Y., Yang G. et aL. Adiponectin/(FBGxFIns) as a predictor of insuLin sensitivity and metaboLic syndrome in patients with poLycystic ovary syndrome // Medicine (BaLtimore). 2016. VoL. 95, N 49. P. e5524.
36. Matsuhisa M., Yamasaki Y., Emoto M. et aL. A noveL index of insuLin resistance determined from the homeostasis modeL assessment index and adiponectin LeveLs in Japanese subjects // Diabetes Res. CLin. Pract. 2007. VoL. 77, N 1. P. 151-154.
37. ViLeLa B.S., Vasques A.C., Cassani R.S. et aL. The HOMA-Adiponectin (HOMA-AD) cLoseLy mirrors the HOMA-IR index in the screening of insuLin resistance in the BraziLian MetaboLic Syndrome Study (BRAMS) // PLoS One. 2016. VoL. 11, N 8. ArticLe ID e0158751.
38. Lim S., Quon M.J., Koh K.K. et aL. ModuLation of adiponectin as a potentiaL therapeutic strategy // AtheroscLerosis. 2014. VoL. 233, N 2. P. 721-728.
39. Su J.R., Lu Z.H., Su Y. et aL. ReLationship of serum adiponectin LeveLs and metformin therapy in patients with type 2 diabetes // Horm. Metab. Res. 2016. VoL. 48, N 2. P. 92-98.
40. Hibuse T., Maeda N., Kishida K. et aL. A piLot three-month sitagLiptin treatment increases serum adiponectin LeveL in Japanese patients with type 2 diabetes meLLitus - a randomized controLLed triaL START-J study // Cardiovasc. DiabetoL. 2014. VoL. 13. P. 96.
41. Liu X., Men P., Wang Y. et aL. Impact of dipeptidyL peptidase-4 inhibitors on serum adiponectin: a meta-anaLysis // Lipids HeaLth Dis. 2016. VoL. 15, N 1. P. 204.
42. Li D., Xu X., Zhang Y. et aL. LiragLutide treatment causes upreguLation of adiponectin and down-reguLation of resistin in Chinese type 2 diabetes // Diabetes Res. CLin. Pract. 2015. VoL. 110, N 2. P. 224-228.
43. HuLsmans M., Geeraert B., ArnouLd T. et aL. PPAR agonist-induced reduction of Mcp1 in atheroscLerotic pLaques of obese, insuLin-resistant mice depends on adiponectin-induced Irak3 expression // PLoS One. 2013. VoL. 8, N 4. ArticLe ID e62253.
44. Zhu Z. BR 08-1 high sodium intake reduction in diabetes with hypertension // J. Hypertens. 2016. VoL. 34, suppL. 1. P. e544.
45. Han J.H., Oh T.J., Lee G. et aL. The beneficiaL effects of empagLifLozin, an SGLT2 inhibitor, on atheroscLerosis in ApoE -/- mice fed a western diet // DiabetoLogia. 2017. VoL. 60, N 2. P. 364-376.
46. Okamoto A., Yokokawa H., Sanada H., Naito T. Changes in LeveLs of biomarkers associated with adipocyte function and insuLin and gLucagon kinetics during treatment with dapagLifLozin among obese type 2 diabetes meLLitus patients // Drugs R. D. 2016. VoL. 16, N 3. P. 255-261.
47. Su X., Yan H., Huang Y. et aL. Expression of FABP4, adipsin and adiponectin in Paneth ceLLs is moduLated by gut LactobaciLLus // Sci. Rep. 2015. VoL. 5. ArticLe ID 18588.
48. Taira R., Yamaguchi S., Shimizu K. et aL. BacteriaL ceLL waLL components reguLate adipokine secretion from visceraL adipocytes // J. CLin. Biochem. Nutr. 2015. VoL. 56, N 2. P. 149-154.
49. Kurotani K., Sato M., Yasuda K. et aL. Even- and odd-chain saturated fatty acids in serum phosphoLipids are differentiaLLy associated with adipokines // PLoS One. 2017. VoL. 12, N 5. ArticLe ID e0178192.
REFERENCES
1. Nakashima R., Yamane K., Kamei N., et aL. Low serum LeveLs of totaL and high-moLecuLar-weight adiponectin predict the deveLopment of metaboLic syndrome in Japanese-Americans. J EndocrinoL Invest. 2011; 34 (8): 615-9.
2. Ametov A.S., Kamynina L.L., Akhmedova Z.G. Type 2 diabetes meLLitus: cLinicaL aspects of genetics, nutrigenetics, and pharmacogenetics. Terapevticheskiy arkhiv [Therapeutic Archive]. 2015; 87 (8): 124-31. (in Russian).
3. de Luis D.A., IzaoLa O., de La Fuente B., et aL. rs1501299 PoLymorphism in the adiponectin gene and their association with totaL adiponectin LeveLs, insuLin resistance and metaboLic syndrome in obese subjects. Ann Nutr Metab. 2016; 69 (3-4): 226-31.
4. Riestra P., Gebreab S.Y., Xu R., et aL. Gender-specific associations between ADIPOQ gene poLymorphisms and adiponectin LeveLs and obesity in the Jackson Heart Study cohort BMC Med Genet. 2015; 16: 65.
5. HoLLand W.L., Xia J.Y., Johnson J.A., et aL. InducibLe overexpression of adiponectin receptors highLight the roLes of adiponectin-induced ceramidase signaLing in Lipid and gLucose homeostasis. MoL Metab. 2017; 6 (3): 267-75.
6. EL Husseny M.W., Mamdouh M., Shaban S., et aL. Adipokines: potentiaL therapeutic targets for vascuLar dysfunction in type II diabetes meLLitus and obesity. J Diabetes Res. 2017; 2017: 8095926.
7. Pashentseva A., Verbovoy A., Sharonova L. Adiponectin: bioLogicaL and pathophysioLogicaL effects. Vrach [Physician]. 2016; (8): 12-5. (in Russian).
8. Tereshchenko I.V., Kamenskikh Ya.A., SusLina A.A. Adiponectin in heaLth and disease. Terapevticheskiy arkhiv [Therapeutic Archive]. 2016; 88 (12): 126-32. (in Russian) 9. Ruan H., Dong L.Q. Adiponectin signaLing and function in insuLin target tissues. J MoL CeLL BioL. 2016; 8 (2): 101-9.
10. Liu Z., Xiao T., Peng X., et aL. APPLs: more than just adiponectin receptor binding proteins. CeLL SignaL. 2017; 32: 76-84.
11. Reibe-PaL S., Febbraio M.A. Adiponectin serenades ceramidase to improve metaboLism. MoL Metab. 2017; 6 (3): 233-5.
12. Weber K.S., Strassburger K., Pacini G., et aL. CircuLating adiponectin concentration is inverseLy associated with gLucose toLerance and insuLin secretion in peopLe with newLy diagnosed diabetes. Diabet Med. 2017; 34 (2): 239-44.
13. Ntzouvani A., FragopouLou E., Panagiotakos D., et aL. Reduced circuLating adiponectin LeveLs are associated with the metaboLic syndrome independentLy of obesity, Lipid indices and serum insuLin LeveLs: a cross-sectionaL study. Lipids HeaLth Dis. 2016; 15 (1): 140.
14. Banerjee A., Khemka V.K., Roy D., et aL. RoLe of serum adiponectin and vitamin D in prediabetes and diabetes meLLitus. Can J Diabetes. 2017; 41 (3): 259-65.
15. Zhang J., Xia L., Zhang F., et aL. A noveL mechanism of diabetic vascuLar endotheLiaL dysfunction: hypoadiponectinemia-induced NLRP3 infLammasome activation. Biochim Biophys Acta. 2017; 1863 (6): 1556-67.
16. Zhao W., Wu C., Li S., Chen X. Adiponectin protects paLmitic acid induced endotheLiaL infLammation and insuLin resistance via reguLating ROS/IKKβ pathways. Cytokine. 2016; 88: 167-76.
17. Okamoto Y. Adiponectin provides cardiovascuLar protection in metaboLic syndrome. CardioL Res Pract. 2011; 2011: 313179.
18. Gorgui J., Gasbarrino K., Georgakis M.K., et aL. CircuLating adiponectin LeveLs in reLation to carotid atheroscLerotic pLaque presence, ischemic stroke risk, and mortaLity: a systematic review and meta-anaLyses. MetaboLism. 2017; 69: 51-66.
19. Kizer J.R. Adiponectin, cardiovascuLar disease, and mortaLity: parsing the duaL prognostic impLications of a compLex adipokine. MetaboLism. 2014; 63 (9): 1079-83.
20. BeLaLcazar L.M., Lang W., Haffner S.M., et aL. Improving adiponectin LeveLs in individuaLs with diabetes and obesity: insights from Look AHEAD. Diabetes Care. 2015; 38 (8): 1544-50.
21. Gasbarrino K., Gorgui J., Nauche B., et aL. CircuLating adiponectin and carotid intima-media thickness: a systematic review and meta-anaLysis. MetaboLism. 2016; 65 (7): 968-86.
22. Gasbarrino K., Zheng H., Hafiane A., et aL. Decreased adiponectin-mediated signaLing through the AdipoR2 pathway is associated with carotid pLaque instabiLity. Stroke. 2017; 48 (4): 915-24.
23. Sente T., Van Berendoncks A.M., Hoymans V.Y., Vrints C.J. Adiponectin resistance in skeLetaL muscLe: pathophysioLogicaL impLications in chronic heart faiLure. J Cachexia Sarcopenia MuscLe. 2016; 7 (3): 261-74.
24. Sente T., Gevaert A., Van Berendoncks A., et aL. The evoLving roLe of adiponectin as an additive biomarker in HFrEF. Heart FaiL Rev. 2016; 21 (6): 753-69.
25. Peri-Okonny P.A., Ayers C., MaaLouf N., et aL. Adiponectin predicts against incident hypertension independent of body fat distribution: observations from the DaLLas Heart Study. Diabetes Metab Res Rev. 2017; 33 (2).
26. Kim D.H., Kim C., Ding E.L., et aL. Adiponectin LeveLs and the risk of hypertension: a systematic review and meta-anaLysis. Hypertension. 2013; 62 (1): 27-32.
27. Lopez-JaramiLLo P., Gomez-ArbeLaez D., Lopez-Lopez J., et aL. The roLe of Leptin/adiponectin ratio in metaboLic syndrome and diabetes. Horm MoL BioL CLin Investig. 2014; 18 (1): 37-45.
28. Kim J.Y., Yadav D., Ahn S.V., Koh S.B. A prospective study of serum adiponectin and regression of metaboLic syndrome: the ARIRANG study. Biochem Biophys Res Commun. 2015; 466 (2): 201-5.
29. Kang D.R., Yadav D., Koh S.B., et aL. Impact of serum Leptin to adiponectin ratio on regression of metaboLic syndrome in high-risk individuaLs: the ARIRANG Study. Yonsei Med J. 2017; 58 (2): 339-46.
30. Iwan-Zietek I., Ruszkowska-Ciastek B., MichaLska M., et aL. Association of adiponectin and Leptin-to-adiponectin ratio with the function of pLateLets in morbidLy obese patients. J PhysioL PharmacoL. 2016; 67 (4): 555-61.
31. Bairwa S.C., Rajapurohitam V., Gan X.T., et aL. Cardiomyocyte antihypertrophic effect of adipose tissue conditioned medium from rats and its abrogation by obesity is mediated by the Leptin to adiponectin ratio. PLoS One. 2016; 11 (1): e0145992.
32. DuLLaart R.P., Gruppen E.G., ConneLLy M.A., et aL. GLycA, a biomarker of infLammatory gLycoproteins, is more cLoseLy reLated to the Leptin/adiponectin ratio than to gLucose toLerance status. CLin Biochem. 2015; 48 (12): 811-4.
33. Gumanova N.G., GavriLova N.E., Chernushevich O.I., et aL. Ratios of Leptin to insuLin and adiponectin to endotheLin are sex-dependentLy associated with extent of coronary atheroscLerosis. Biomarkers. 2017; 22 (3-4): 239-45.
34. Upadhyaya S., Kadamkode V., Mahammed R., et aL. Adiponectin and IL-6: mediators of infLammation in progression of heaLthy to type 2 diabetes in Indian popuLation. Adipocyte. 2014; 3 (1): 39-45.
35. Xu X., Lai Y., Yang G., et aL. Adiponectin/(FBGxFIns) as a predictor of insuLin sensitivity and metaboLic syndrome in patients with poLycystic ovary syndrome. Medicine (BaLtimore). 2016; 95 (49): e5524.
36. Matsuhisa M., Yamasaki Y., Emoto M., et aL. A noveL index of insuLin resistance determined from the homeostasis modeL assessment index and adiponectin LeveLs in Japanese subjects. Diabetes Res CLin Pract. 2007; 77 (1): 151-4.
37. ViLeLa B.S., Vasques A.C., Cassani R.S., et aL. The HOMA-Adiponectin (HOMA-AD) cLoseLy mirrors the HOMA-IR index in the screening of insuLin resistance in the BraziLian MetaboLic Syndrome Study (BRAMS). PLoS One. 2016; 11 (8): e0158751.
38. Lim S., Quon M.J., Koh K.K., et aL. ModuLation of adiponectin as a potentiaL therapeutic strategy. AtheroscLerosis. 2014; 233 (2): 721-8.
39. Su J.R., Lu Z.H., Su Y., et aL. ReLationship of serum adiponectin LeveLs and metformin therapy in patients with type 2 diabetes. Horm Metab Res. 2016; 48 (2): 92-8.
40. Hibuse T., Maeda N., Kishida K., et aL. A piLot three-month sitagLiptin treatment increases serum adiponectin LeveL in Japanese patients with type 2 diabetes meLLitus - a randomized controLLed triaL START-J study. Cardiovasc DiabetoL. 2014; 13: 96.
41. Liu X., Men P., Wang Y., et aL. Impact of dipeptidyL peptidase-4 inhibitors on serum adiponectin: a meta-anaLysis. Lipids HeaLth Dis. 2016; 15 (1): 204.
42. Li D., Xu X., Zhang Y., et aL. LiragLutide treatment causes upreguLation of adiponectin and downreguLation of resistin in Chinese type 2 diabetes. Diabetes Res CLin Pract. 2015; 110 (2): 224-8.
43. HuLsmans M., Geeraert B., ArnouLd T., et aL. PPAR agonist-induced reduction of Mcp1 in atheroscLerotic pLaques of obese, insuLin-resistant mice depends on adiponectin-induced Irak3 expression. PLoS One. 2013; 8( 4): e62253.
44. Zhu Z. BR 08-1 high sodium intake reduction in diabetes with hypertension. J Hypertens. 2016; 34 (1): e544.
45. Han J.H., Oh T.J., Lee G., et aL. The beneficiaL effects of empagLifLozin, an SGLT2 inhibitor, on atheroscLerosis in ApoE -/- mice fed a western diet. DiabetoLogia. 2017; 60 (2): 364-76.
46. Okamoto A., Yokokawa H., Sanada H., Naito T., et aL. Changes in LeveLs of biomarkers associated with adipocyte function and insuLin and gLucagon kinetics during treatment with dapagLifLozin among obese type 2 diabetes meLLitus patients. Drugs R D. 2016; 16 (3): 255-61.
47. Su X., Yan H., Huang Y., et aL. Expression of FABP4, adipsin and adiponectin in Paneth ceLLs is moduLated by gut LactobaciLLus. Sci Rep. 2015; 5: 18588.
48. Taira R., Yamaguchi S., Shimizu K., et aL. BacteriaL ceLL waLL components reguLate adipokine secretion from visceraL adipocytes. J CLin Biochem Nutr. 2015; 56 (2): 149-54.
49. Kurotani K., Sato M., Yasuda K., et aL. Even- and odd-chain saturated fatty acids in serum phosphoLipids are differentiaLLy associated with adipokines. PLoS One. 2017; 12 (5): e0178192.